ADRO - Aduro BioTech, Inc.
| Previous Close | 1.1800 |
| Open | 1.1800 |
| Bid | 1.1200 x 3000 |
| Ask | 1.2400 x 4000 |
| Day's Range | 1.1100 - 1.2000 |
| 52 Week Range | 0.9010 - 4.5900 |
| Volume | 778,545 |
| Avg. Volume | 700,730 |
| Market Cap | 90M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1190 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Insider Monkey
Hedge Funds Are Betting On Aduro BioTech Inc (ADRO)
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Aduro BioTech Inc (NASDAQ:ADRO) based on that […]
- Simply Wall St.
Does Aduro BioTech, Inc. (NASDAQ:ADRO) Have A Volatile Share Price?
If you own shares in Aduro BioTech, Inc. (NASDAQ:ADRO) then it's worth thinking about how it contributes to the...
- Zacks
Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that its license partner, Merck & Co., Inc. (known as MSD outside the United States and Canada), presented data from an ongoing Phase 1 clinical trial of MK-5890, an anti-CD27 agonist. MK-5890 is being evaluated as monotherapy and in combination with KEYTRUDA® (pembrolizumab), an approved anti-PD-1 antibody, in adults with advanced solid tumors.
- Zacks
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
- Zacks
Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -13.04% and 5.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results
BERKELEY, Calif., Nov. 07, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
- Simply Wall St.
Should You Worry About Aduro BioTech, Inc.'s (NASDAQ:ADRO) CEO Pay?
Steve Isaacs became the CEO of Aduro BioTech, Inc. (NASDAQ:ADRO) in 2008. This report will, first, examine the CEO...
- GlobeNewswire
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019. The abstracts, which will be presented in a poster session, include a clinical trial in progress description of the Phase 2 study of ADU-S100 (MIW815) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), as well as nonclinical data on the role of TNF-alpha signaling on STING agonists.
- GlobeNewswire
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
BERKELEY, Calif., Sept. 30, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the.
- Simply Wall St.
Do Insiders Own Lots Of Shares In Aduro BioTech, Inc. (NASDAQ:ADRO)?
The big shareholder groups in Aduro BioTech, Inc. (NASDAQ:ADRO) have power over the company. Generally speaking, as a...
- GlobeNewswire
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
BERKELEY, Calif., Sept. 04, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
- GlobeNewswire
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference
BERKELEY, Calif., Sept. 03, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
- Zacks
Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report?
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Who Has Been Selling Aduro BioTech, Inc. (NASDAQ:ADRO) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Zacks
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
- GlobeNewswire
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
BERKELEY, Calif., Aug. 01, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
- Zacks
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
- Zacks
Aduro Stock Crashes After ASCO Updates on Cancer Candidate
Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.
- GlobeNewswire
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. Aduro’s ADU-S100 (MIW815), a novel STING pathway activator, is being evaluated in combination with Novartis’ spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody, in patients with advanced solid tumors or lymphomas.
- GlobeNewswire
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Cancer Center, is a principal investigator for the Phase 1 study of STING pathway activator ADU-S100 (MIW815) in combination with spartalizumab (PDR001), Novartis’ investigational anti-PD-1 monoclonal antibody, in patients with advanced/metastatic solid tumors or lymphomas.
- GlobeNewswire
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided an update on its clinical development programs for BION-1301, a first-in-class humanized IgG4 monoclonal antibody that fully blocks APRIL binding to both the BCMA and TACI receptors.
- Zacks
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates
Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.
